On September 10, 2012, Navidea Biopharma (AMEX: NAVB) announced that it had received a complete response letter (CRL) from the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE